Venetoclax for Refractory Myeloid Sarcoma
Abraham S. Kanate(HonorHealth), Michael Chargualaf(Daiichi Sankyo (United States)), Jeffrey A. Vos(West Virginia University)
Cited by 25
Related Papers
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2020|278
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
|Blood|2015|273
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
|Blood|2017|247
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
|Journal of Clinical Oncology|2024|211
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|183